These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 24088145)
1. Parallel problems: Applying institutional corruption analysis of Congress to big pharma. Fields G J Law Med Ethics; 2013; 41(3):556-60. PubMed ID: 24088145 [TBL] [Abstract][Full Text] [Related]
2. Conflicts of interest, institutional corruption, and pharma: an agenda for reform. Rodwin MA J Law Med Ethics; 2012; 40(3):511-22. PubMed ID: 23061578 [TBL] [Abstract][Full Text] [Related]
3. Introduction: Institutional corruption and the pharmaceutical policy. Rodwin MA J Law Med Ethics; 2013; 41(3):544-52. PubMed ID: 24088143 [TBL] [Abstract][Full Text] [Related]
4. Pharmaceuticals, political money, and public policy: a theoretical and empirical agenda. Jorgensen PD J Law Med Ethics; 2013; 41(3):561-70. PubMed ID: 24088146 [TBL] [Abstract][Full Text] [Related]
5. Drug development. Corruption and research fraud send big chill through big pharma in China. Hvistendahl M Science; 2013 Aug; 341(6145):445-6. PubMed ID: 23908198 [No Abstract] [Full Text] [Related]
6. Why We Must Talk About Institutional Corruption to Understand Wrongdoing in the Health Sector Comment on "We Need to Talk About Corruption in Health Systems". Fotaki M Int J Health Policy Manag; 2020 May; 9(5):206-208. PubMed ID: 32563221 [TBL] [Abstract][Full Text] [Related]
7. Research funding, conflicts of interest, and the meta-methodology of public relations. Rampton S; Stauber J Public Health Rep; 2002; 117(4):331-9. PubMed ID: 12477914 [No Abstract] [Full Text] [Related]
8. Foreword: "Institutional corruption" defined. Lessig L J Law Med Ethics; 2013; 41(3):553-5. PubMed ID: 24088144 [No Abstract] [Full Text] [Related]
9. Political contributions from the health and insurance industries. Makinson L Health Aff (Millwood); 1992; 11(4):119-34. PubMed ID: 1483631 [TBL] [Abstract][Full Text] [Related]
10. Drug firms, the codification of diagnostic categories, and bias in clinical guidelines. Cosgrove L; Wheeler EE J Law Med Ethics; 2013; 41(3):644-53. PubMed ID: 24088155 [TBL] [Abstract][Full Text] [Related]
11. Individual and Institutional Corruption in European and US Healthcare: Overview and Link of Various Corruption Typologies. Sommersguter-Reichmann M; Wild C; Stepan A; Reichmann G; Fried A Appl Health Econ Health Policy; 2018 Jun; 16(3):289-302. PubMed ID: 29572725 [TBL] [Abstract][Full Text] [Related]
12. Scientific misconduct, the pharmaceutical industry, and the tragedy of institutions. Cohen-Kohler JC; Esmail LC Med Law; 2007 Sep; 26(3):431-46. PubMed ID: 17970244 [TBL] [Abstract][Full Text] [Related]
13. If only it were so: medical physics, U.S. human radiation experiments, and the Final Report of the President's Advisory Committee (ACHRE). Martensen R Med Humanit Rev; 1997; 11(2):21-36. PubMed ID: 11645853 [No Abstract] [Full Text] [Related]
14. Is disclosure of potential conflicts of interest in medicine and public health sufficient to increase transparency and decrease corruption? Spelsberg A; Martiny A; Schoenhoefer PS; J Epidemiol Community Health; 2009 Aug; 63(8):603-5. PubMed ID: 19596840 [No Abstract] [Full Text] [Related]
15. Big pharma often commits corporate crime, and this must be stopped. Gøtzsche PC BMJ; 2012 Dec; 345():e8462. PubMed ID: 23241451 [No Abstract] [Full Text] [Related]
17. Profits and plagiarism: the case of medical ghostwriting. Anekwe TD Bioethics; 2010 Jul; 24(6):267-72. PubMed ID: 19222448 [TBL] [Abstract][Full Text] [Related]
18. Corruption: Engineers are Victims, Perpetrators or Both? Pecujlija M; Cosic I; Nesic-Grubic L; Drobnjak S Sci Eng Ethics; 2015 Aug; 21(4):907-23. PubMed ID: 24935245 [TBL] [Abstract][Full Text] [Related]
19. When conflict-of-interest is a factor in scientific misconduct. Krimsky S Med Law; 2007 Sep; 26(3):447-63. PubMed ID: 17970245 [TBL] [Abstract][Full Text] [Related]
20. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. Light DW; Lexchin J; Darrow JJ J Law Med Ethics; 2013; 41(3):590-600. PubMed ID: 24088149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]